SG11201808717QA - Phosphaplatin liquid formulations - Google Patents
Phosphaplatin liquid formulationsInfo
- Publication number
- SG11201808717QA SG11201808717QA SG11201808717QA SG11201808717QA SG11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA SG 11201808717Q A SG11201808717Q A SG 11201808717QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- phosphaplatin
- liquid formulations
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD IIIII0110111 11111 010111110111010111111111111111011111111111111110111111 (43) International Bureau 0.. .1 j International Publication Date ..... ...,/ (10) International Publication Number WO 2017/176880 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/28 (2006.01) C07F 15/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/026139 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 5 April 2017 (05.04.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/319,047 6 April 2016 (06.04.2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: PHOSPLATIN THERAPEUTICS LLC kind [US/US]; 1350 Avenue of the Americas, New York, NY GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 10019 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: LUKE, Wayne, D.; 208 Jennings Street, West TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Lafayette, IN 47906 (US). AMES, Tyler; 41-17 Crescent EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, St., #12c, Long Island City, NY 11101 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (74) Agents: LIU, Wansheng Jerry et al.; Fox Rothchild LLP, GW, KM, ML, MR, NE, SN, TD, TG). 997 Lenox Drive, Building 3, Lawrenceville, NJ 08648- Published: 2311 (US). — with international search report (Art. 21(3)) (54) Title: PHOSPHAPLATIN LIQUID FORMULATIONS = 1 meta PT-112 Solutions at 2$°C./60%Ri.1 IMP% OS% 00% t q t SS% 00% 7 5% ,,,,, t ', ,,,,,,N,‘ I I I 70% 65% I Neb it , At , • -f - 4 ,- 1-1 © c3C OW days a Tse dale freafkdays 00 IN ,-1 FIG. 1 N 1-1 (57) : Pharmaceutical compositions of phosphaplatin compounds, in particular buffered stable liquid formulations of pyro - 0 dach-2 ready for use in the treatment of various cancers, and methods of preparation are disclosed. ei C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319047P | 2016-04-06 | 2016-04-06 | |
| PCT/US2017/026139 WO2017176880A1 (en) | 2016-04-06 | 2017-04-05 | Phosphaplatin liquid formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808717QA true SG11201808717QA (en) | 2018-11-29 |
Family
ID=60000715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808717QA SG11201808717QA (en) | 2016-04-06 | 2017-04-05 | Phosphaplatin liquid formulations |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11154529B2 (en) |
| EP (1) | EP3439650A4 (en) |
| JP (2) | JP2019510831A (en) |
| KR (1) | KR102419247B1 (en) |
| CN (1) | CN109310663B (en) |
| AU (1) | AU2017246883B2 (en) |
| BR (1) | BR112018070603A2 (en) |
| CA (1) | CA3020166A1 (en) |
| CL (1) | CL2018002848A1 (en) |
| CO (1) | CO2018011420A2 (en) |
| EA (1) | EA039525B1 (en) |
| IL (1) | IL262066A (en) |
| MX (1) | MX2018012223A (en) |
| PH (1) | PH12018502139A1 (en) |
| SG (1) | SG11201808717QA (en) |
| TW (1) | TWI798175B (en) |
| WO (1) | WO2017176880A1 (en) |
| ZA (1) | ZA201806530B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565561A4 (en) * | 2017-01-06 | 2020-08-26 | Phosplatin Therapeutics LLC | Phosphaplatin compounds as therapeutic agents for treatment of bone blood cancers |
| US20240009212A1 (en) * | 2020-10-20 | 2024-01-11 | Promontory Therapeutics Inc. | Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2530279A1 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
| RS55714B1 (en) * | 2010-06-04 | 2017-07-31 | Univ Ohio | Phosphaplatins and their use for treatment of cancers |
| WO2012096722A1 (en) | 2011-01-12 | 2012-07-19 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| WO2013052839A1 (en) | 2011-10-05 | 2013-04-11 | Bose Rathindra N | Efficient processes for large scale preparation of phosphaplatins antitumor agents |
| EP2763537B1 (en) * | 2011-10-05 | 2018-01-10 | Rathindra N. Bose | Efficient processes for large scale preparation of phosphaplatins antitumor agents |
| SI3202769T1 (en) | 2012-05-24 | 2020-02-28 | Phosplatin Therapeutics Llc | Purification method for phosphaplatin compounds |
-
2017
- 2017-04-05 SG SG11201808717QA patent/SG11201808717QA/en unknown
- 2017-04-05 WO PCT/US2017/026139 patent/WO2017176880A1/en active Application Filing
- 2017-04-05 KR KR1020187032250A patent/KR102419247B1/en active IP Right Grant
- 2017-04-05 AU AU2017246883A patent/AU2017246883B2/en active Active
- 2017-04-05 EA EA201892157A patent/EA039525B1/en unknown
- 2017-04-05 CA CA3020166A patent/CA3020166A1/en active Pending
- 2017-04-05 CN CN201780034766.3A patent/CN109310663B/en active Active
- 2017-04-05 US US16/091,873 patent/US11154529B2/en active Active
- 2017-04-05 BR BR112018070603A patent/BR112018070603A2/en active Search and Examination
- 2017-04-05 TW TW106111384A patent/TWI798175B/en active
- 2017-04-05 MX MX2018012223A patent/MX2018012223A/en unknown
- 2017-04-05 EP EP17779744.6A patent/EP3439650A4/en active Pending
- 2017-04-05 JP JP2019503631A patent/JP2019510831A/en active Pending
-
2018
- 2018-10-02 IL IL262066A patent/IL262066A/en active IP Right Grant
- 2018-10-02 ZA ZA2018/06530A patent/ZA201806530B/en unknown
- 2018-10-04 PH PH12018502139A patent/PH12018502139A1/en unknown
- 2018-10-05 CL CL2018002848A patent/CL2018002848A1/en unknown
- 2018-10-25 CO CONC2018/0011420A patent/CO2018011420A2/en unknown
-
2022
- 2022-11-04 JP JP2022177576A patent/JP2023014110A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201806530B (en) | 2019-07-31 |
| PH12018502139A1 (en) | 2019-09-23 |
| EA201892157A1 (en) | 2019-04-30 |
| IL262066A (en) | 2018-11-29 |
| JP2023014110A (en) | 2023-01-26 |
| EP3439650A4 (en) | 2019-12-11 |
| AU2017246883A1 (en) | 2018-11-08 |
| EP3439650A1 (en) | 2019-02-13 |
| TW201737920A (en) | 2017-11-01 |
| US11154529B2 (en) | 2021-10-26 |
| JP2019510831A (en) | 2019-04-18 |
| CN109310663A (en) | 2019-02-05 |
| TWI798175B (en) | 2023-04-11 |
| BR112018070603A2 (en) | 2019-02-05 |
| CL2018002848A1 (en) | 2018-12-21 |
| CA3020166A1 (en) | 2017-10-12 |
| CN109310663B (en) | 2022-05-31 |
| KR20180133889A (en) | 2018-12-17 |
| AU2017246883B2 (en) | 2023-02-09 |
| WO2017176880A1 (en) | 2017-10-12 |
| EA039525B1 (en) | 2022-02-07 |
| MX2018012223A (en) | 2019-05-30 |
| US20200323810A1 (en) | 2020-10-15 |
| KR102419247B1 (en) | 2022-07-11 |
| CO2018011420A2 (en) | 2019-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804934PA (en) | Novel Compounds | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201809292WA (en) | Abdominal and core exerciser device | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |